Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen and AstraZeneca have announced that TEZSPIRE™ (tezepelumab-ekko) is now available in the U.S. for severe asthma treatment following FDA approval on Dec. 17, 2021. This first-in-class biologic targets TSLP and is designed for a broad population, addressing unmet medical needs. Clinical trials showed significant reductions in asthma attacks without limitations based on eosinophilic or allergic profiles. Common side effects include pharyngitis and arthralgia. The companies aim to provide affordable access through the Tezspire Together Program.
Amgen and Arrakis Therapeutics have formed a collaboration to develop RNA degrader therapeutics targeting difficult-to-drug proteins across various therapeutic areas. Amgen will pay $75 million upfront for five initial programs, with potential payments reaching several billion for milestone achievements. This partnership leverages Amgen's expertise in multispecific molecules and Arrakis' RNA-targeted small molecule platform to create innovative treatments for previously undruggable targets. The collaboration may significantly expand Amgen's drug development capabilities.
Amgen has awarded the second Amgen Golden Ticket to Karma Biotechnologies, granting them a year of lab space at BioLabs LA at the Lundquist Institute. This initiative aims to bolster life science startups in Southern California, with Karma receiving benefits such as access to Amgen's business leaders. Karma's Xavine™ platform focuses on treating autoimmune diseases. The Golden Ticket program, now in its 26th iteration, is part of Amgen's commitment to support biotech innovation across various hubs including San Francisco and Boston.
Amgen has received conditional marketing authorization from the European Commission for LUMYKRAS (sotorasib), a KRASG12C inhibitor to treat advanced non-small cell lung cancer (NSCLC) in adults after prior therapy. This approval, following a positive recommendation from the CHMP, is based on the CodeBreaK 100 clinical trial results, showing a 37.1% objective response rate and an 11.1-month median duration of response. With this authorization, Amgen aims to provide a critical treatment option for European patients affected by this challenging cancer.
Amgen (NASDAQ:AMGN) will virtually present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. CEO Robert A. Bradway will lead the presentation. The live audio will be available for media, investors, and the public via Amgen's website, where it will also be archived for at least 90 days. Amgen is renowned for its innovative human therapeutics, focusing on high unmet medical needs since its inception in 1980. It is part of the Dow Jones Industrial Average and Nasdaq-100, recognized as one of the world's best workplaces and sustainable companies.
Amgen has entered a research collaboration with Generate Biomedicines to develop protein therapeutics targeting five clinical indications. Amgen will provide
Amgen will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 1:00 p.m. ET. The presentation will be led by Robert A. Bradway, the CEO. The live audio will be available for public access via Amgen's website. This event underscores Amgen's commitment to addressing serious illnesses through innovative therapeutics. The webcast will also be archived for at least 90 days for those unable to attend live.
Amgen announced FDA approval for Otezla® (apremilast) to treat adults with plaque psoriasis, making it the first oral treatment approved for all severity levels. The approval stems from the Phase 3 ADVANCE trial, which showed significant efficacy, with 21.6% achieving treatment success at week 16 compared to 4.1% for placebo (p<0.0001). Otezla, which has been used by over 650,000 patients globally, offers an alternative for those inadequately managed by topical therapies. Approximately 8 million Americans suffer from plaque psoriasis, indicating a substantial market opportunity for Amgen.
Amgen has announced the FDA approval of Tezspire (tezepelumab-ekko), a first-in-class biologic for severe asthma treatment in patients aged 12 and older. This landmark approval allows it to be used without phenotypic limitations, targeting inflammation directly. Tezspire outperformed placebos in the NAVIGATOR Phase 3 trial across primary and secondary endpoints. The drug aims to aid the 34 million individuals suffering from severe asthma worldwide, offering a new treatment option for those previously inadequately addressed by existing therapies.
Amgen (NASDAQ: AMGN) announced new data from its hematology pipeline to be presented at the 63rd ASH Annual Meeting from Dec. 11-14, 2021. The data emphasizes Amgen's dedication to improving patient outcomes in blood cancers. Key presentations include updated Phase 3 trial results for BLINCYTO showing improved survival rates in children with B-ALL, and promising safety and efficacy data for subcutaneous BLINCYTO in adults. Results from the Pregnancy Surveillance Program for Nplate highlighted no significant safety concerns. Important abstracts detailing real-world outcomes in multiple myeloma will also be presented.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
